Abiopharma

🔍 Chernett Jorey (Executive)

Company: Airsculpt Technologies, Inc. (AIRS)

Report Date: 2026-04-17

Detailed Transactions and Holdings:

• Acquired 40,000 shares of Common Stock at $2.54 per share (Direct)
  Date: 2026-04-17 | Code: P | equity_swap_involved: 0 | shares_owned_after: 7,053,761.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 200,400 shares of Call Option (AIRS 17APR26 $4C) at $4.0 per share (Derivative)
  Date: 2026-04-17 | Code: E | Expires: 2026-04-17 | Exercise: 2026-04-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2
• Sold 200,000 shares of Call Option (AIRS 17APR26 $5C) at $5.0 per share (Derivative)
  Date: 2026-04-17 | Code: E | Expires: 2026-04-17 | Exercise: 2026-04-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.56, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
• F2: These call options expired unexercised on April 17, 2026, as the market price of the underlying common stock was below the exercise price of the options at the time of expiration. No consideration was received by the Reporting Person in connection with this expiration.
• REMARKS: The filing of this Form 4 constitutes an exit filing for the Reporting Person.